Traws Pharma, Inc.

{
  "main_header": {
    "sid": 1158544,
    "name": "Traws Pharma, Inc.",
    "stock_name": "Traws Pharma, Inc.",
    "full_name": "Traws Pharma, Inc.",
    "name_url": "stocks-analysis/traws-pharma-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "1.72",
    "chg": -0.32,
    "chgp": "-15.69%",
    "dir": -1,
    "prev_price": "2.04",
    "mcapval": "19.42",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US68232V8019",
    "curr_date": "Feb 05",
    "curr_time": "",
    "bse_nse_vol": "551.21 k",
    "exc_status": "Active",
    "traded_date": "Feb 05, 2026",
    "traded_date_str": "2026 02 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/traws-pharma-inc-1158544-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Traws Pharma, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-traws-pharma-inc-overvalued-or-undervalued-3723359",
        "imagepath": "",
        "date": "2025-11-23 11:10:54",
        "description": "As of 21 November 2025, the valuation grade for Traws Pharma, Inc. moved from attractive to very attractive. The company appears to be undervalued based on its financial metrics. Key ratios include a Price to Book Value of 1.53, an EV to EBIT of 0.14, and an impressive ROE of 939.05%. \n\nIn comparison to its peers, Traws Pharma's P/E ratio of 0.2145 stands in stark contrast to Catalyst Biosciences, Inc., which has a P/E of 110.0436, indicating that Traws is significantly cheaper relative to its earnings potential. Additionally, while the industry faces challenges, Traws Pharma's strong ROCE of 496.52% highlights its efficient use of capital. Despite recent struggles, with a YTD return of -73.99% compared to the S&P 500's 12.26%, the long-term outlook remains promising, especially with a 3-year return of 156.67%...."
      },
      {
        "title": "Is Traws Pharma, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-traws-pharma-inc-overvalued-or-undervalued-3711426",
        "imagepath": "",
        "date": "2025-11-18 11:13:59",
        "description": "As of 14 November 2025, Traws Pharma, Inc. has moved from a very attractive to an attractive valuation grade. The company appears to be undervalued based on its valuation ratios, including a Price to Book Value of 1.53, an EV to EBIT of 0.14, and an impressive ROE of 939.05%. In comparison to peers, Catalyst Biosciences, Inc. is considered expensive with a P/E of 110.04, while Elutia, Inc. is classified as risky with a P/E of -2.83, highlighting Traws Pharma's relatively favorable position.\n\nDespite the recent stock performance showing a significant decline year-to-date of -76.58% compared to a 14.49% return for the S&P 500, the long-term perspective over three years reveals a strong return of 136.36%, which suggests potential recovery and growth ahead. Overall, Traws Pharma, Inc. is positioned as an undervalued opportunity in the pharmaceuticals and biotechnology sector...."
      },
      {
        "title": "Is Traws Pharma, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-traws-pharma-inc-overvalued-or-undervalued-3706953",
        "imagepath": "",
        "date": "2025-11-17 11:08:10",
        "description": "As of 14 November 2025, Traws Pharma, Inc. has moved from a very attractive to an attractive valuation grade. The company appears to be undervalued based on its current metrics, particularly with a Price to Book Value of 1.53, an EV to EBIT of 0.14, and an impressive ROE of 939.05%. \n\nWhen compared to peers, Traws Pharma's P/E ratio of 0.2145 stands in stark contrast to Catalyst Biosciences, Inc., which is considered expensive at a P/E of 110.0436, and Elutia, Inc., which has a risky valuation with a P/E of -2.8330. This suggests that Traws Pharma may offer a more favorable investment opportunity relative to its peers. Although specific return data is not available, the lack of negative returns compared to the S&P 500 reinforces the notion that Traws Pharma is positioned well in the market...."
      },
      {
        "title": "Is Traws Pharma, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-traws-pharma-inc-overvalued-or-undervalued-3705592",
        "imagepath": "",
        "date": "2025-11-16 11:04:57",
        "description": "As of 14 November 2025, Traws Pharma, Inc. has moved from a very attractive to an attractive valuation grade. The company appears to be undervalued, particularly when considering its P/E ratio of 0, EV to EBIT of 0.14, and a remarkably high ROE of 939.05%. In comparison to peers, Catalyst Biosciences, Inc. is deemed expensive with a P/E of 110.04, while Elutia, Inc. is classified as risky with an EV to EBITDA of -5.54.\n\nDespite the attractive valuation metrics, Traws Pharma has faced significant challenges, as evidenced by its year-to-date return of -75.56%, contrasting sharply with the S&P 500's positive return of 14.49% during the same period. This stark difference highlights the market's skepticism regarding the company's future prospects, despite its strong valuation ratios...."
      }
    ],
    "total": 12,
    "sid": "1158544",
    "stock_news_url": "https://www.marketsmojo.com/news/traws-pharma-inc-1158544"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Traws Pharma, Inc. overvalued or undervalued?

2025-11-23 11:10:54

As of 21 November 2025, the valuation grade for Traws Pharma, Inc. moved from attractive to very attractive. The company appears to be undervalued based on its financial metrics. Key ratios include a Price to Book Value of 1.53, an EV to EBIT of 0.14, and an impressive ROE of 939.05%. In comparison to its peers, Traws Pharma's P/E ratio of 0.2145 stands in stark contrast to Catalyst Biosciences, Inc., which has a P/E of 110.0436, indicating that Traws is significantly cheaper relative to its earnings potential. Additionally, while the industry faces challenges, Traws Pharma's strong ROCE of 496.52% highlights its efficient use of capital. Despite recent struggles, with a YTD return of -73.99% compared to the S&P 500's 12.26%, the long-term outlook remains promising, especially with a 3-year return of 156.67%....

Read full news article

Is Traws Pharma, Inc. overvalued or undervalued?

2025-11-18 11:13:59

As of 14 November 2025, Traws Pharma, Inc. has moved from a very attractive to an attractive valuation grade. The company appears to be undervalued based on its valuation ratios, including a Price to Book Value of 1.53, an EV to EBIT of 0.14, and an impressive ROE of 939.05%. In comparison to peers, Catalyst Biosciences, Inc. is considered expensive with a P/E of 110.04, while Elutia, Inc. is classified as risky with a P/E of -2.83, highlighting Traws Pharma's relatively favorable position. Despite the recent stock performance showing a significant decline year-to-date of -76.58% compared to a 14.49% return for the S&P 500, the long-term perspective over three years reveals a strong return of 136.36%, which suggests potential recovery and growth ahead. Overall, Traws Pharma, Inc. is positioned as an undervalued opportunity in the pharmaceuticals and biotechnology sector....

Read full news article

Is Traws Pharma, Inc. overvalued or undervalued?

2025-11-17 11:08:10

As of 14 November 2025, Traws Pharma, Inc. has moved from a very attractive to an attractive valuation grade. The company appears to be undervalued based on its current metrics, particularly with a Price to Book Value of 1.53, an EV to EBIT of 0.14, and an impressive ROE of 939.05%. When compared to peers, Traws Pharma's P/E ratio of 0.2145 stands in stark contrast to Catalyst Biosciences, Inc., which is considered expensive at a P/E of 110.0436, and Elutia, Inc., which has a risky valuation with a P/E of -2.8330. This suggests that Traws Pharma may offer a more favorable investment opportunity relative to its peers. Although specific return data is not available, the lack of negative returns compared to the S&P 500 reinforces the notion that Traws Pharma is positioned well in the market....

Read full news article

Is Traws Pharma, Inc. overvalued or undervalued?

2025-11-16 11:04:57

As of 14 November 2025, Traws Pharma, Inc. has moved from a very attractive to an attractive valuation grade. The company appears to be undervalued, particularly when considering its P/E ratio of 0, EV to EBIT of 0.14, and a remarkably high ROE of 939.05%. In comparison to peers, Catalyst Biosciences, Inc. is deemed expensive with a P/E of 110.04, while Elutia, Inc. is classified as risky with an EV to EBITDA of -5.54. Despite the attractive valuation metrics, Traws Pharma has faced significant challenges, as evidenced by its year-to-date return of -75.56%, contrasting sharply with the S&P 500's positive return of 14.49% during the same period. This stark difference highlights the market's skepticism regarding the company's future prospects, despite its strong valuation ratios....

Read full news article

View All News